Downstream Processing Featured Articles

81. Investigational Brain Cancer Vaccine To Be Tested In Phase I Roswell Park Study 9/27/2012

    A new clinical research study at Roswell Park Cancer Institute(RPCI) will test a first-of-its-kind cancer “vaccine” that may prove effective against many forms of solid-tumor cancers.

82. MicroRNAs Can Convert Normal Cells Into Cancer Promoters 11/21/2012

    Unraveling the mechanism that ovarian cancer cells use to change normal cells around them into cells that promote tumor growth has identified several new targets for treatment of this deadly disease.

83. GE Healthcare Launches FF High Performance Nitrocellulose Membranes Optimized For Diagnostic Assay Reproducibility 8/1/2012

    GE Healthcare Life Sciences’ new Whatman FF High Performance (HP) membrane provides the industry with a new diagnostic membrane to enable fast, razor-sharp line separation and highly reproducible results for the detection of target molecules in liquids such as water, urine, blood and saliva.

84. Tweaking Gene Expression To Repair Lungs 2/25/2013

    Lung diseases such as asthma and chronic obstructive pulmonary disease (COPD) are on the rise, according to the American Lung Association and the National Institutes of Health.

85. Study Identifies Human Melanoma Stem Cells 8/23/2012

    Cancer stem cells are defined by three abilities: differentiation, self-renewal and their ability to seed a tumor. These stem cells resist chemotherapy and many researchers posit their role in relapse.

86. Phenex Enters Into A Research Collaboration And License Agreement With Janssen For Autoimmune And Chronic Inflammatory Disorders 12/17/2012

    Phenex Pharmaceuticals AG (Phenex) today announced it has entered into an agreement with Janssen Biotech, Inc. and its affiliates (Janssen) to jointly discover compounds that target the nuclear hormone receptor RORγT and may have utility in the treatment of chronic autoimmune and inflammatory disorders including rheumatoid arthritis, psoriasis, and inflammatory bowel disease.

87. Roche And BioLamina Start Collaboration To Develop Novel Cell Culture Systems 3/6/2013

    BioLamina, Stockholm, Sweden and Roche recently announced the signing of a research and development agreement to jointly develop new cell culture systems for various applications, including stem cell research.

88. Frost & Sullivan Lauds Pfenex Inc. For Developing A Protein Expression Platform That Delivers Unparalleled Success And Speed 6/5/2012

    Based on its comprehensive  TEAM Research rigorous 10 step evaluation methodology, Frost & Sullivan has awarded Pfenex Inc. with the 2012 North American Enabling Technology Award in Microbial Expression Technology.

89. FDA Approval Pushes Novartis Into 21st Century Vaccine Development 6/18/2014

    In 2009, the world experienced a global threat in the form of H1N1. Despite a prompt response to the need for a vaccine in the United States, it was still not available until six months later and not enough doses were even produced to cover all Americans. During the year-long battle with the deadly virus, the CDC estimates between 8,870 and 18,300 people died due to H1N1-related complications. In the world of influenza vaccine production using chicken eggs, the response experienced during the H1N1 outbreak is not uncommon. Is this the best our industry can do? Novartis says NO.

90. Rockland Immunochemicals Acquires TrueBlot Product Line 12/13/2012

    Rockland Immunochemicals Inc., a biotechnology company focusing on antibodies and antibody based tools for basic research, assay development, and preclinical studies, recently announced the acquisition of the TrueBlot IP/Western blot product line from eBioscience, Inc., an Affymetrix company.